Sarepta Therapeutics · 4 hours ago
Data Science & Biometrics Intern
United States
Internship
Hybrid
Intern
$21/hr - $26/hrSarepta Therapeutics is at the forefront of genetic medicine, focusing on Duchenne muscular dystrophy and other diseases. The Data Science Intern will support analytical projects across R&D, working with experienced data scientists to build tools and models that aid in drug development.
BiotechnologyGeneticsHealth CareTherapeutics
No H1B
Responsibilities
Contribute to the development or enhancement of R Shiny applications used across the Data Science team
Assist with updates, documentation, and testing for internal R packages
Support data visualization and reporting workflows that improve team efficiency and insight generation
Collaborate on machine learning model development to support safety‑related research questions
Assist in data preparation, exploratory analyses, feature engineering, and model evaluation
Help summarize findings and communicate model performance to scientific stakeholders
Support GenAI‑based initiatives that enhance productivity across the Biometrics function
Participate in prototyping, prompt design, and evaluation of GenAI workflows
Assist in identifying opportunities where GenAI can accelerate statistical programming, documentation, or analysis processes
Qualification
Required
Currently pursuing a bachelor's degree in data science, Biostatistics, Computer Science, Applied Mathematics, Computational Biology, or related discipline
Foundational experience with R; familiarity with Shiny, Python, or machine learning principles is a plus
Interest in applying analytics to real‑world scientific and clinical challenges
Curiosity about biotech/pharma and how data supports drug development
Strong problem‑solving skills and eagerness to learn new tools and methods
Ability to organize work effectively, communicate clearly, and collaborate with cross‑functional partners
Benefits
Competitive compensation and benefit package
Company
Sarepta Therapeutics
Sarepta Therapeutics focuses on the discovery and development of precision genetic medicine to treat rare diseases.
Founded in 1980
501-1000 employees
Funding
Current Stage
Public CompanyTotal Funding
$2.88BKey Investors
Michael Andrew ChambersPharmakon AdvisorsMidCap Financial
2025-12-11Post Ipo Debt· $291.4M
2025-08-21Post Ipo Equity
2025-08-21Post Ipo Debt· $602M
Leadership Team
Ian Estepan
Executive Vice President, Chief Financial Officer
K
Kathy Behrens Wilsey
Director
Recent News
2026-01-24
Genetic Engineering News
2026-01-23
Company data provided by crunchbase